NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled
NCT00150462 2017-05-02Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological MalignanciesAmgenPhase 1 Completed48 enrolled 26 charts